Protocol Ledger

NCT06603220 · Phase II · COMPLETED

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Interventional Phase II clinical trial protocol NCT06603220 sponsored by Evommune in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-14 Enrollment: 30 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06603220
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06603220
Protocol FieldVerified Registry Value
NCT IdentifierNCT06603220
Consolidated Lead SponsorEvommune
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment30 participants (ACTUAL)
Registered Start Date2024-08-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06603220
Hospital Research SiteLocationSite Profile
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI